GENEMEDICS APP

GENEMEDICS NUTRITION

Vasoactive Intestinal Peptide

Author: Dr. George Shanlikian, M.D.  |   Last Updated: June 5th, 2025

Share This Page

Book a Free Consultation

Potential Health Benefits of Vasoactive Intestinal Peptide

Vasoactive Intestinal Peptide benefits include promoting smooth muscle relaxation for improved digestion, enhancing enzyme and electrolyte secretion, and providing anti-inflammatory effects that support gut health and mucosal integrity. These functions aid in nutrient absorption, prevent constipation, and may help manage conditions like inflammatory bowel disease.

  • Lowers the risk of heart disease [1-12]
  • Promotes healthy lungs [13-24]
  • Promotes wound healing [25-34]
  • Regulates blood pressure [35-43]
  • Promotes a healthy digestive system [44-56]
  • Prevents cancer [57-64]
  • Boosts immunity [65-77]
  • Improves mental health [78-84]

Key Takeaways

  • Regulates Gastrointestinal Motility: VIP helps relax smooth muscles in the gastrointestinal tract, promoting efficient movement of food and preventing issues like constipation and bloating.
  • Stimulates Digestive Secretions: It enhances the secretion of water, electrolytes, and digestive enzymes, supporting nutrient absorption and maintaining hydration balance in the intestines.
  • Supports Pancreatic Function: VIP stimulates the pancreas to release bicarbonate and digestive enzymes, which aid in breaking down food and neutralizing stomach acid.
  • Anti-Inflammatory Effects: It plays a role in modulating immune responses within the gut, reducing inflammation and protecting against conditions like inflammatory bowel disease (IBD).
  • Neuroprotective and Cardiovascular Benefits: Beyond digestion, VIP has broader systemic effects, including neuroprotection, vasodilation, and regulation of heart function, contributing to overall health and well-being.

What is Vasoactive Intestinal Peptide?

Vasoactive intestinal peptide (VIP) is a peptide hormone of 28 amino acids. It is found in the intestines, pancreas, and central nervous system. It is involved in various important bodily functions such as heart contraction, blood circulation, energy production, blood pressure regulation, and smooth muscle relaxation.

How Vasoactive Intestinal Peptide Works

Vasoactive intestinal peptide is a potent vasodilator. This means that it causes the blood vessels and smooth muscles to relax or dilate. As a result, blood flow to the different body parts is significantly improved. Since blood is rich in oxygen and essential nutrients, the relaxing effects of vasoactive intestinal peptide on the blood vessels and smooth muscles can help benefit every body system.

Chemical Structure

Research on Vasoactive Intestinal Peptide

A. Lowers the Risk of Heart Disease

Vasoactive intestinal peptide (VIP) lowers the risk of heart disease through its potent vasodilatory, anti-inflammatory, and cardioprotective effects. VIP relaxes blood vessels by stimulating nitric oxide production, which helps reduce blood pressure and improve blood flow, thereby decreasing the strain on the heart. It also has anti-inflammatory properties that inhibit the production of pro-inflammatory cytokines, reducing vascular inflammation and preventing atherosclerosis. Additionally, VIP has antioxidant effects that protect against oxidative stress, which is a key factor in the development of cardiovascular diseases. These combined actions make VIP a promising target for therapeutic strategies aimed at preventing and managing heart disease.

  1. A study showed that VIP is important for maintaining normal blood flow to the heart. [1]
  2. In patients with heart failure (HF) due to dilated cardiomyopathy, increased VIP levels in the blood were associated with restoration of blood flow. [2]
  3. A study showed that a low concentration of VIP was associated with a higher risk of coronary disease. [3]
  4. In mouse models, injection of VIP reduced injury from myocarditis (heart muscle inflammation) and decreased the number and size of plaques caused by atherosclerosis. [4]
  5. A study reported that combined administration of VIP and pituitary adenylatecyclase-activating peptide (PACAP) protected against heart disease. [5]
  6. In patients with HF, decreased concentration of VIP led to worsening of symptoms while increased levels improved blood flow to the heart. [6]
  7. Vasoactive intestinal polypeptide (VIP) is present in coronary artery nerves and plays a role in coronary vasoregulation, as demonstrated by its varying concentrations in different artery segments and its ability to induce significant vasodilation in the left anterior descending artery. [7]
  8. Vasoactive intestinal peptide (VIP) improves myocardial function during ischemia and reperfusion by enhancing left ventricular function, reducing tissue injury, modulating calcium transients, and decreasing oxidative stress, making it a potential cardioprotective agent. [8]
  9. VIP affects atrial electrophysiology by modulating ion channels, shortening action potential duration, reducing conduction velocity, and increasing spatial heterogeneity, which may contribute to atrial fibrillation vulnerability in conditions with elevated VIP release. [9]
  10. VIP acts as a coronary vasodilator in humans, reducing coronary vascular resistance through both direct and indirect mechanisms without prostaglandin mediation, while also increasing myocardial oxygen uptake. [10]
  11. VIP is crucial for maintaining circadian rhythms in heart rate and cardiac clock gene expression, as its deficiency disrupts these rhythms without causing structural cardiac defects. [11]
  12. VIP infusion increases myocardial VIP levels and reduces myocardial fibrosis, suggesting its potential as a therapeutic target for treating heart failure. [12]

B. Promotes Healthy Lungs

Promotes Healthy Lungs

Vasoactive Intestinal Peptide (VIP) promotes healthy lung function by acting as a potent bronchodilator and anti-inflammatory agent within the respiratory system. It helps relax the smooth muscles of the airways, improving airflow and reducing bronchoconstriction, which is beneficial for individuals with conditions like asthma and chronic obstructive pulmonary disease (COPD). Additionally, VIP has immunomodulatory properties that help reduce inflammation and prevent excessive immune responses that can contribute to respiratory conditions. It also supports the production of surfactant, a substance that keeps the lungs’ air sacs open and prevents collapse, ensuring efficient gas exchange. Through these mechanisms, VIP plays a crucial role in maintaining optimal lung function and respiratory health.

  1. A study found that VIP can help improve lung function and protect against pulmonary disorders. [13]
  2. In patients with pulmonary sarcoidosis (lung inflammation and scarring), VIP inhalation through a nebulizer produced anti-inflammatory effects. [14]
  3. A study found that VIP-based agents can be used in the treatment of various pulmonary diseases. [15]
  4. A review of several studies presented the potential role of inhaled VIP as an alternative drug for lung disease. [16]
  5. A study showed that VIPā€™s anti-inflammatory effects could play a role in treating asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease. [17]
  6. A study reported that VIP decreased cell injury induced by high oxygen levels, which in turn reduced the progression of lung impairment. [18]
  7. Vasoactive intestinal peptide deficiency in primary pulmonary hypertension suggests its therapeutic potential, as supplementation improves hemodynamics and prognosis without side effects. [19]
  8. Although vasoactive intestinal peptide (VIP) analog Aviptadil did not significantly improve the primary endpoint in COVID-19 respiratory failure, it doubled the odds of survival at 60 days, improved respiratory function, reduced cytokine release, and showed potential benefits, especially in patients on high-flow nasal oxygen or mechanical ventilation. [20]
  9. Inhaled vasoactive intestinal peptide (VIP) analog Aviptadil caused modest, short-lived pulmonary vasodilation, improved stroke volume and oxygenation in some pulmonary hypertension patients, reduced right ventricular workload without systemic effects, and showed a good safety profile, warranting further study for chronic treatment. [21]
  10. Adding vasoactive intestinal peptide (VIP) to University of Wisconsin (UW) solution significantly improved lung preservation, extending viability to 24 hours while maintaining functional capacity after reperfusion. [22]
  11. Vasoactive intestinal peptide (VIP), a neurotransmitter discovered in 1970, has gained renewed interest for its potential in treating COVID-19 and various lung diseases, though its therapeutic use faces limitations addressed by extended-release formulations and analogues. [23]
  12. Adding vasoactive intestinal peptide (VIP) to pneumoplegic solutions improves lung preservation by reducing vascular edema and mitochondrial damage, suggesting its potential as an important additive for enhancing donor lung quality before transplantation. [24]

C. Promotes Wound Healing

Vasoactive Intestinal Peptide (VIP) promotes wound healing by enhancing tissue repair processes through its anti-inflammatory and immunomodulatory properties. It helps regulate immune cell activity, reducing excessive inflammation that can delay healing while promoting a balanced response that supports tissue regeneration. VIP also stimulates the production of growth factors and collagen, which are essential for rebuilding damaged tissues and maintaining skin integrity. Additionally, its vasodilatory effects improve blood flow to the wound site, ensuring an adequate supply of oxygen and nutrients necessary for efficient healing. These combined actions make VIP a potential therapeutic target for enhancing wound recovery in conditions involving chronic wounds or impaired healing, such as diabetes and autoimmune disorders.

  1. In human bronchial epithelial cells (HBEC), VIP produced protective effects against cell damage and promoted wound recovery. [25]
  2. In rabbits, VIP injection accelerated the healing of alkali-induced corneal burns. [26]
  3. In mice, VIP-coated wound dressings were effective in promoting wound healing by stimulating tissue and blood vessel growth. [27]
  4. In diabetic mice, VIP boosted wound healing by regulating inflammation and nerve regeneration. [28]
  5. In mice, VIP treatment has been shown to increase the survival rate of the transplanted cornea. [29]
  6. Vasoactive intestinal peptide (VIP) plays a crucial role in regulating intestinal immunity and has shown potential as an anti-inflammatory and immune modulator in ulcerative colitis (UC). By influencing regulatory B cells (Bregs) and their secretion of IL-10, VIP helps modulate immune tolerance, offering a promising strategy for UC treatment. [30]
  7. Vasoactive intestinal peptide (VIP) is a potent vasodilator that significantly lowers blood pressure and heart rate while redistributing blood flow to priority organs like the brain and heart. However, exogenous VIP administration impairs skin perfusion in both normal and burned tissue, likely due to increased sympathetic vasoconstriction aimed at maintaining blood pressure. [31]
  8. Vasoactive intestinal peptide (VIP) promotes wound healing in human bronchial epithelial cells (HBEC) through intracellular signaling pathways involving PKA, PKC, ERK, and calmodulin. Inhibiting these pathways reduces VIP-induced cell migration, proliferation, and E-cadherin expression, highlighting their role in airway epithelial repair. [32]
  9. Vasoactive intestinal peptide (VIP) enhances wound healing and proliferation of human bronchial epithelial cells (HBECs) by activating CREB via PKA- and ERK-dependent pathways. Inhibiting CREB, PKA, or ERK reduces VIP-mediated protective effects, highlighting CREBā€™s crucial role in airway epithelial repair. [33]
  10. Vasoactive intestinal peptide (VIP) promotes fracture healing by counteracting the negative effects of sympathetic nervous system inhibition, as shown in sympathectomized mice with impaired bone structure and healing. VIP treatment restored bone micro-architecture, mechanical properties, and osteogenic marker expression, suggesting its potential as a therapeutic strategy for fracture repair. [34]

D. Regulates Blood Pressure

Vasoactive Intestinal Peptide (VIP) helps regulate blood pressure by acting as a potent vasodilator, meaning it relaxes the smooth muscle in blood vessel walls, leading to their widening and improved blood flow. This vasodilation reduces vascular resistance, which in turn lowers blood pressure and promotes better circulation to vital organs. VIP also influences the balance of fluid and electrolytes by stimulating the secretion of water and salts in the intestines, indirectly contributing to blood pressure regulation. Additionally, VIP has anti-inflammatory and cardioprotective properties that help protect blood vessels from damage and dysfunction, further supporting healthy blood pressure levels.

  1. In hamsters, the administration of encapsulated VIP was effective in lowering blood pressure. [35]
  2. In healthy patients, VIPā€™s blood vessel-dilating properties lowered systemic blood pressure. [36]
  3. In cats, VIP increased blood flow while lowering blood pressure. [37]
  4. Patients with obstructive sleep apnea syndrome (OSAS) exhibit decreased plasma NO levels in the morning, indicating possible endothelial dysfunction, while VIP levels correlate with nocturnal blood pressure changes. These findings suggest that VIP may play a role in regulating blood pressure during sleep in OSAS patients. [38]
  5. VIP lowers perfusion pressure and enhances coronary blood flow, suggesting its potential role in regulating blood pressure and cardiovascular function. [39]
  6. VIP stimulates renin secretion through a humoral mechanism rather than neural release from renal nerves, as evidenced by increased plasma renin activity following elevated circulating VIP levels, though its role in renin elevation due to low-salt diet or hemorrhage appears unlikely. [40]
  7. VIP lowers blood pressure and increases renal nerve activity through baroreceptor activation, while CCK’s cardiovascular effects are mediated by vagal afferents and central nervous system action, indicating distinct regulatory mechanisms for these peptides. [41]
  8. VIP induces potent vasodilation, reducing peripheral resistance and mean arterial pressure while initially increasing cardiac output and later decreasing stroke volume, with compensatory tachycardia helping to maintain blood pressure, mirroring cardiovascular effects seen in pancreatic cholera syndrome. [42]
  9. As a powerful vasodilator and neuromodulator, vasoactive intestinal peptide (VIP) enhances coronary blood flow, reduces vascular resistance, and increases cardiac contractility by activating adenylyl cyclase and nitric oxide pathways. [43]

E. Promotes a Healthy Digestive System

Vasoactive Intestinal Peptide (VIP) promotes a healthy digestive system by facilitating smooth muscle relaxation, enhancing the secretion of digestive fluids, regulating gastric acid secretion, and maintaining gut integrity. It helps regulate intestinal motility, ensuring the smooth passage of food and preventing conditions such as bloating and constipation. Additionally, VIP stimulates the release of water, electrolytes, and digestive enzymes, which are essential for breaking down food and absorbing nutrients effectively. Its anti-inflammatory properties further support gut health by reducing inflammation and protecting the intestinal lining, which is crucial for individuals with conditions like irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD). By maintaining a balanced digestive environment, VIP contributes to overall gastrointestinal health and function.

  1. In mice, VIP maintained microbiota balance in the digestive system. [44]
  2. A study suggested that VIP plays a significant role in the excretion of body fat. [45]
  3. Studies also reported that VIP can help improve gastrointestinal function by increasing blood flow to the different structures in the gut and regulating the secretion of gastric acid. [46-47]
  4. In mice, VIP administration had a beneficial therapeutic effect in necrotizing enterocolitis (NEC) by reducing inflammation and tight junction disruption. [48]
  5. A study showed that VIP and its analogues have the potential as inflammatory mediators in intestinal disease, heart disease, and neuroinflammatory conditions. [49-50]
  6. VIP plays a crucial role in intestinal immune defense by regulating the recruitment of group 3 innate lymphoid cells (ILC3s) to the gut through VPAC1, independent of microbiota or adaptive immunity. Mice lacking VIP or VPAC1 show reduced intestinal ILC3 populations, impaired IL-22 production, and increased susceptibility to Citrobacter rodentium infection, which can be mitigated by RA supplementation, ILC3 transfer, or recombinant IL-22. [51]
  7. In severe acute pancreatitis (SAP), gut barrier dysfunction is driven by increased endotoxin levels and inflammatory cytokines, but treatment with VIP helps counteract these effects. VIP administration reduced TNF-Ī± and IL-6 while boosting IL-10, leading to decreased intestinal injury and inflammation, demonstrating its protective role in maintaining gut integrity. [52]
  8. Gastrointestinal motility is influenced by microbial composition, which regulates cholinergic nerve function through jejunal VIP, highlighting its potential as a therapeutic target for motility disorders. [53]
  9. VIP plays a crucial role in maintaining intestinal homeostasis by regulating epithelial progenitor cell proliferation and differentiation, while also enhancing regeneration following radiation-induced injury. [54]
  10. VIP is essential for maintaining colonic epithelial barrier integrity, supporting cell proliferation and migration, and regulating goblet cell function, while also playing a protective role in colitis by promoting epithelial repair and homeostasis. [55]
  11. Deficiency of vasoactive intestinal peptide (VIP) disrupts colonic epithelial barrier integrity, impairs cell proliferation and goblet cell function, and increases susceptibility to colitis, while exogenous VIP treatment restores epithelial homeostasis and protects against inflammation. [56]

F. Prevents Cancer

Vasoactive Intestinal Peptide (VIP) has been shown to possess anti-cancer properties by modulating immune responses, reducing inflammation, and promoting cellular homeostasis. It exerts its effects by binding to specific receptors on immune cells, enhancing their ability to regulate inflammation and prevent the uncontrolled cell growth that can lead to cancer. VIP also has antioxidant properties that help protect cells from oxidative stress, a known factor in cancer development. Additionally, it influences cell signaling pathways that regulate cell proliferation and apoptosis (programmed cell death), preventing the formation and spread of tumors. Studies suggest that VIP may have potential therapeutic applications in cancers such as colorectal, lung, and pancreatic cancer due to its ability to inhibit tumor growth and support the body’s natural defense mechanisms

  1. A study showed that VIP prevents cancer progression by controlling cell migration. [57]
  2. A study found that VIP has a tumor-regressing effect against gastrointestinal cancers. [58]
  3. In breast cancer cells, VIP inhibited the growth and multiplication of cancer cells. [59-60]
  4. A recombinant vasoactive intestinal peptide analogue (rVIPa) alleviates TNBS-induced colonic injury and inflammation in rats by reducing TNF-Ī± and endotoxin levels, increasing IL-10 and tight junction proteins, and modulating the TLR4/NF-ĪŗB signaling pathway, suggesting its potential as a therapeutic option for intestinal inflammatory disorders and related cancers. [61]
  5. VIP is highly expressed in gastric adenocarcinoma, while its receptors are less active, suggesting a role in tumor regulation. Although VIP does not promote cancer cell growth, its antagonist increases proliferation, indicating that VIP may help slow gastric cancer progression. [62]
  6. A lipophilic VIP analog (SNH) enhances the effectiveness of various chemotherapy drugs in colon and lung cancer. Combining SNH with chemotherapy may improve treatment response while reducing side effects by allowing lower drug doses. [63]
  7. VIP inhibits hepatocellular carcinoma (HCC) growth by inducing apoptosis through the cAMP/Bcl-xL pathway. It increases caspase-3 while reducing Bcl-xL and CREB, suggesting a potential therapeutic role in HCC treatment. [64]

G. Boosts Immunity

Vasoactive Intestinal Peptide (VIP) boosts immunity by acting as a potent immunomodulator that helps regulate the balance between pro-inflammatory and anti-inflammatory responses. It promotes the production of anti-inflammatory cytokines while inhibiting the release of pro-inflammatory molecules, thereby preventing excessive immune reactions that can lead to chronic inflammation and autoimmune conditions. VIP also supports the function of regulatory T cells (Tregs), which play a crucial role in maintaining immune tolerance and preventing the immune system from attacking the body’s own tissues. Additionally, it enhances the integrity of mucosal barriers in the gut and lungs, which are the body’s first line of defense against pathogens, reducing susceptibility to infections and inflammation-related disorders.

  1. In animal studies, VIP showed great therapeutic potential against inflammatory diseases. [65]
  2. A study suggested that VIP modulates the bodyā€™s immune tolerance by regulating the balance between pro-inflammatory and anti-inflammatory substances. [66]
  3. In murine cytomegalovirus (mCMV) infected mice, VIP injection significantly increased the survival rates of the subjects by enhancing their innate and adaptive cellular immunity. [67]
  4. VIP helps protect the intestinal mucosal immune barrier by regulating mast cell activity. L. casei ATCC 393 relies on VIP signaling to reduce inflammation and maintain gut health during ETEC K88 infection. [68]
  5. VIP enhances oral tolerance by reducing immune responses, including inflammation and antibody production. It likely works through the VPAC2 receptor to regulate both cellular and humoral immunity. [69]
  6. A study reveals how VIP links the nervous and immune systems to protect the gut. By activating ILCs, it enhances resistance to pathogens encountered during food intake. [70]
  7. A study highlights VIPā€™s role in preserving immune regulatory function in rheumatoid arthritis. It prevents IL-10 mRNA decay in RegMos, suggesting potential therapeutic benefits for immune disorders. [71]
  8. VIP plays a key role in regulating immune responses in ulcerative colitis (UC). It enhances IL-10 production by regulatory B cells (Bregs), which helps restore immune balance and may offer a new treatment approach. [72]
  9. Neural and immune interactions are crucial for defense mechanisms, with VIP being a key immunoregulatory neuropeptide. It modulates immune responses and may be involved in autoimmune conditions by influencing Th17 cell differentiation. [73]
  10. The VIP-VPAC signaling axis is central to immune modulation, influencing various immune cells. Its involvement in Th17 cell differentiation provides new insights into immune regulation and disease treatment. [74]
  11. VIP and its receptors, VPAC1 and VPAC2, play a key role in regulating immune responses. Transgenic mice overexpressing VPAC2 in CD4 T cells exhibit increased Th2 responses, while VPAC2-null mice show enhanced Th1 responses. [75]
  12. VIP regulates Breg function in intestinal immunity. Patients with IgE+ ulcerative colitis (UC) have lower VIP and IL-10 levels, impairing Breg-mediated immune suppression. [76]
  13. VIP maintains immune homeostasis and regulates inflammation. It modulates both anti- and pro-inflammatory mediators through receptors on immune cells. [77]

H. Improves Mental Health

Vasoactive Intestinal Peptide (VIP) has been shown to have neuroprotective effects, which may contribute to improved mental health. It helps regulate the release of neurotransmitters, promotes neuronal growth, and protects brain cells from oxidative stress, all of which are essential for maintaining cognitive function and emotional well-being. VIP also plays a role in modulating the immune response in the brain, potentially reducing neuroinflammation, a key factor in many neuropsychiatric disorders, such as depression and anxiety. Additionally, VIPā€™s ability to enhance blood flow and reduce stress responses may support overall brain health, promoting a sense of calm and mental clarity.

  1. A review of several studies discussed the potential therapeutic role of VIP in treating neurological disorders such as Alzheimerā€™s disease, Parkinsonā€™s disease, and Autism spectrum disorders. [78]
  2. A study reported that VIP exerts its neuroprotective effects by inhibiting the loss of neurons in the brain. [79]
  3. VIP reduces amyloid plaques in Alzheimer’s disease. In a study using 5xFAD mice, chronic VIP treatment significantly decreased AĪ²40 and AĪ²42 plaques, particularly in the subiculum and cortical areas. [80]
  4. Given its strong anti-inflammatory and neuroprotective effects, VIP may serve as a promising therapeutic agent for disorders like multiple sclerosis, Parkinsonā€™s, and Alzheimerā€™s disease. [81]
  5. With its antioxidant, anti-inflammatory, neurotrophic, and anti-apoptotic properties, VIP may help regulate neuroinflammation, oxidative stress, and neuronal survival, making it a promising candidate for Parkinsonā€™s treatment. [82]
  6. Dysregulated VIP may contribute to neurodevelopmental disorders. Abnormal VIP signaling has been linked to conditions like autism, Down syndrome, and fetal alcohol syndrome, suggesting its potential as a therapeutic target. [83]
  7. VIP influences brain connectivity and volume. Higher VIP levels were linked to increased functional connectivity between the amygdala and both the parahippocampus and orbitofrontal cortex, as well as greater brain volume in the left amygdala and lateral orbitofrontal cortex. [84]

Associated Side Effects of Vasoactive Intestinal Peptide

VIP side effects are very uncommon. There have been some side effects associated with the use of this drug wherein the patient had one of the issues listed below at some point while being on VIP. However, these side effects werenā€™t confirmed to be associated with the treatment and could have been a coincidence and not related to the use of VIP. Despite this, it was listed as a side effect associated with VIP even though these associated side effects are very uncommon.

Side effects associated with VIP may include the following:

  • Dizziness
  • Headaches
  • Irritability
  • Low blood pressure
  • Rash

Vasoactive Intestinal Peptide Nasal Spray

Vasoactive Intestinal Peptide (VIP) nasal spray is a therapeutic option being explored for its potential benefits in treating various inflammatory and neurodegenerative conditions. VIP is a neuropeptide that plays a crucial role in regulating immune function, inflammation, and cellular homeostasis. By delivering VIP via a nasal spray, it bypasses the digestive system and enters the bloodstream more directly, potentially enhancing its bioavailability and therapeutic effects.

Research suggests that VIP nasal spray may be beneficial for conditions such as chronic inflammatory response syndrome (CIRS), pulmonary hypertension, and certain neurological disorders. Its anti-inflammatory and immunomodulatory properties make it a promising candidate for reducing systemic inflammation and improving respiratory function. Some studies also indicate its potential to support cognitive function and neuroprotection, which could be valuable in conditions like Alzheimer’s disease.

Despite its potential, VIP nasal spray is not yet widely available and is primarily used in research settings or as part of specialized treatment protocols. Concerns regarding its long-term safety, optimal dosing, and regulatory approval remain areas of ongoing investigation. Patients considering VIP therapy should consult healthcare providers to weigh the potential benefits against any risks and to ensure its appropriate use in their treatment plans.

What is Vasoactive Intestinal Peptide Receptor?

Vasoactive Intestinal Peptide Receptor (VIPR) is a type of receptor that binds to vasoactive intestinal peptide (VIP), a neuropeptide involved in various physiological functions. VIPRs are G-protein-coupled receptors (GPCRs) that mediate the effects of VIP by triggering intracellular signaling pathways, such as the activation of adenylyl cyclase and increased cyclic adenosine monophosphate (cAMP) levels. These receptors are widely distributed in the body, including the central nervous system, gastrointestinal tract, and immune cells.

VIPRs play a crucial role in regulating smooth muscle relaxation, vasodilation, and secretion of fluids in the gastrointestinal and respiratory systems. In the immune system, they help modulate inflammatory responses by influencing cytokine production and immune cell activity. Due to their diverse functions, VIPRs have been studied for their potential therapeutic applications in conditions such as asthma, chronic inflammatory diseases, and neurodegenerative disorders.

There are two main subtypes of VIP receptors, known as VPAC1 and VPAC2, which differ in their tissue distribution and functional roles. VPAC1 is primarily expressed in the lungs, gastrointestinal tract, and central nervous system, while VPAC2 is more prevalent in the immune system and endocrine glands. Understanding the functions and signaling mechanisms of VIPRs can help develop targeted therapies to harness their benefits in treating various diseases.

Vasoactive Peptides in Burns

Vasoactive peptides play a crucial role in the physiological response to burns, contributing to both the initial injury response and subsequent healing processes. These peptides, such as bradykinin and substance P, are released in response to tissue damage and inflammation. They promote vasodilation, increased vascular permeability, and leukocyte recruitment to the affected area, which can help remove damaged cells and fight infection. However, excessive release can lead to complications like edema, hypotension, and systemic inflammatory responses that exacerbate burn injury severity.

In the acute phase of burn injury, vasoactive peptides can contribute to fluid shifts and capillary leak syndrome, leading to significant fluid loss and hypovolemia. This is a critical concern in burn management, as it requires aggressive fluid resuscitation to maintain organ perfusion and prevent shock. Medications that modulate vasoactive peptide activity, such as angiotensin-converting enzyme (ACE) inhibitors or bradykinin receptor antagonists, are sometimes considered to balance the beneficial and harmful effects of these peptides in burn patients.

Research into the therapeutic modulation of vasoactive peptides in burns is ongoing, with a focus on reducing harmful inflammatory responses while preserving their role in tissue repair. Emerging therapies aim to harness their potential in promoting angiogenesis and wound healing without triggering excessive inflammation. Understanding the precise regulation of vasoactive peptides could lead to targeted treatments that improve outcomes and reduce complications such as infection, scarring, and chronic inflammation in burn patients.

Vasoactive Intestinal Peptide Function

Vasoactive intestinal peptide (VIP) is a neuropeptide that plays a crucial role in regulating various physiological processes within the body. It is primarily produced in the gastrointestinal tract, pancreas, and central nervous system, where it acts as a neurotransmitter and hormone. VIP is known for its ability to induce smooth muscle relaxation, particularly in the digestive and respiratory systems, facilitating processes such as vasodilation, bronchodilation, and gastrointestinal motility.

In addition to its role in smooth muscle relaxation, VIP has significant anti-inflammatory and immunomodulatory effects. It helps regulate immune responses by reducing the production of pro-inflammatory cytokines and promoting the differentiation of regulatory T cells. These actions contribute to its potential therapeutic applications in conditions such as inflammatory bowel disease, autoimmune disorders, and respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD).

Furthermore, VIP influences various endocrine and metabolic functions. It stimulates the secretion of insulin, glucagon, and pancreatic enzymes, aiding in glucose metabolism and digestive processes. Additionally, VIP has neuroprotective effects in the central nervous system, where it supports neuronal survival, neurogenesis, and cognitive function. Due to these diverse functions, VIP continues to be a subject of research for its potential role in treating neurological and metabolic disorders.

What does VIP Peptide Benefits do?

Vasoactive Intestinal Peptide (VIP) is a neuropeptide that plays a crucial role in regulating various physiological functions within the body. It is primarily known for its anti-inflammatory and immunomodulatory effects, helping to regulate immune system responses and maintain balance in inflammatory processes. VIP also acts as a potent vasodilator, which means it helps to relax blood vessels, improving blood flow and supporting cardiovascular health.

One of the key benefits of VIP peptide is its ability to support neurological function and protect against neurodegenerative conditions. Research suggests that VIP can promote brain health by reducing inflammation in the central nervous system and supporting the survival of neurons. This has made VIP a topic of interest in conditions such as Alzheimer’s disease, Parkinsonā€™s disease, and multiple sclerosis, where neuroinflammation plays a significant role in disease progression.

Additionally, VIP peptide is beneficial for gut health and digestion. It helps to regulate intestinal motility, enhance nutrient absorption, and protect the gut lining from inflammation. VIP is also linked to improving conditions such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) by reducing gut inflammation and promoting a balanced gut microbiome. These benefits make VIP an essential peptide for maintaining overall digestive health and well-being.

VIP Peptide Benefits in Digestion

Vasoactive Intestinal Peptide (VIP) is a crucial neuropeptide that plays a significant role in regulating digestion by promoting smooth muscle relaxation in the gastrointestinal (GI) tract. This relaxation helps facilitate the movement of food through the intestines, ensuring efficient digestion and nutrient absorption. VIP also stimulates the secretion of water and electrolytes into the intestines, which aids in maintaining proper hydration and preventing constipation.

In addition to promoting motility and secretion, VIP supports digestion by regulating enzyme release from the pancreas. It enhances the secretion of digestive enzymes and bicarbonate, which helps neutralize stomach acid and break down food components effectively. This function is particularly important for individuals with conditions such as pancreatic insufficiency, where enzyme production is impaired, making VIP a potential therapeutic target.

Furthermore, VIP has protective and anti-inflammatory properties that benefit the digestive system. It helps modulate immune responses in the gut, reducing inflammation and promoting mucosal integrity. These effects can be beneficial for individuals suffering from inflammatory bowel diseases (IBD) such as Crohnā€™s disease and ulcerative colitis, where inflammation disrupts normal digestion and causes discomfort.

Share This Page

FAQ

What does vasoactive intestinal peptide do?

Vasoactive intestinal polypeptide (VIP) regulates smooth muscle relaxation, stimulates water and electrolyte secretion, modulates immune responses, and promotes vasodilation, supporting functions in the digestive, respiratory, and nervous systems. The actions of gastrointestinal hormones like VIP are critical for maintaining homeostasis in these systems. Additionally, gastrointestinal hormones, including VIP, play a significant role in promoting tissue repair and reducing inflammation, as well as having notable cardiovascular effects. VIP’s ability to regulate various gastrointestinal hormones makes it essential for optimal digestive health, immune function, and its cardiovascular effects. Furthermore, the regulation of cardiovascular effects by VIP helps maintain blood pressure and improve circulation, contributing to overall health.

What does VIP do in the gut?

Vasoactive intestinal polypeptide promotes intestinal motility, enhances water and electrolyte secretion, supports enzyme release from the pancreas, and helps maintain gut barrier integrity. The regulation of VIP expression is essential for these processes, as it ensures proper functionality within the digestive system. In addition, vasoactive intestinal polypeptide plays a crucial role in regulating smooth muscle relaxation, which further aids digestion. Studies on VIP expression have shown its significant impact on maintaining gut health, especially in promoting efficient nutrient absorption. Furthermore, VIP also has a connection to the lymph nodes, where immune responses are regulated to maintain overall digestive system health. The actions of vasoactive intestinal polypeptide, closely linked to VIP expression, contribute to overall gut health and efficient nutrient absorption, while also influencing the lymph nodes to modulate immune responses. Through its intricate interaction with the lymph nodes, VIP helps ensure proper immune function during digestion.

What is the action of VIP?

VIP acts as a neurotransmitter and hormone, relaxing smooth muscles, dilating blood vessels, and improving coronary artery blood flow. It also stimulates secretions and regulates immune and inflammatory responses, which can benefit individuals with autoimmune diseases. Furthermore, VIP enhances coronary artery blood flow, ensuring adequate oxygen delivery to the heart muscles. By promoting vasodilation, it supports overall circulation and coronary artery blood flow, making it a potential therapeutic target for autoimmune diseases and cardiovascular health. Additionally, its ability to modulate inflammation highlights its importance in managing autoimmune diseases and reducing related complications.

What is the function of vasoactive intestinal peptide?

VIP supports digestion, modulates immune responses, regulates blood flow to vascular tissues, promotes hydration, and protects vascular tissues by reducing inflammation. Additionally, VIP is closely related to peptide histidine methionine, which also plays a role in regulating physiological processes. Both VIP and peptide histidine methionine contribute to maintaining vascular tissues’ health and reducing inflammation. Research suggests that peptide histidine methionine may work synergistically with VIP to support immune modulation and promote overall well-being. Moreover, cholinergic neurons, which play a key role in neurotransmission, are involved in regulating the release of VIP and other peptides. The interaction between cholinergic neurons and VIP can influence gut motility and the overall digestive process. Understanding how cholinergic neurons influence VIP activity is crucial for exploring new therapeutic approaches to gastrointestinal and vascular health.

What does vasoactive intestinal peptide test for?

A VIP test measures levels in the blood to diagnose conditions like VIPoma or to investigate chronic diarrhea and electrolyte imbalances. VIP is also known for its role in vasodilation, as it decreases coronary vascular resistance, supporting better blood flow. In addition to its diagnostic value, the test can help identify conditions where decreased coronary vascular resistance might play a role, often linked to nerve stimulation. This function highlights VIPā€™s importance in cardiovascular health, where it decreases coronary vascular resistance and promotes efficient circulation, further influenced by nerve stimulation. Additionally, VIPā€™s role in nerve stimulation may also contribute to the regulation of vascular tone and circulation.

What triggers the release of VIP?

VIP is released by neurons in the gut and other tissues, including intestinal mucosal mast cells, in response to food intake, stress, or neural signaling in the autonomic nervous system. The interaction between VIP and intestinal mucosal mast cells plays a crucial role in modulating immune responses and maintaining gut health. Additionally, intestinal mucosal mast cells contribute to the regulation of inflammatory processes influenced by VIP signaling, which is also linked to conditions such as pancreatic cholera. As a widely distributed neuropeptide, VIP is involved in multiple physiological processes throughout the body. In the case of pancreatic cholera, the overproduction of VIP leads to severe diarrhea and electrolyte imbalances, highlighting the peptideā€™s significant role in gut function. Furthermore, the signaling pathways of VIP, a widely distributed neuropeptide, are critical in understanding conditions like pancreatic cholera, where VIPā€™s effects on fluid secretion become pathological. This widely distributed neuropeptide continues to reveal its importance in both normal and pathological states.

What is VIP nasal spray used for?

VIP nasal spray, which contains both VIP and peptide histidine isoleucine, is often used as a treatment for chronic inflammatory response syndrome (CIRS), helping regulate inflammation and support healing. According to J Cell Physiol, the inclusion of both VIP and peptide histidine isoleucine enhances its effectiveness in modulating immune responses and improving tissue health. This makes both VIP and peptide histidine isoleucine important components in managing symptoms of CIRS and promoting recovery. As noted in J Cell Physiol, these peptides contribute to reducing inflammation and promoting cellular repair, providing significant therapeutic benefits in chronic inflammatory conditions. Studies published in J Cell Physiol further suggest that VIP and peptide histidine isoleucine may offer synergistic effects in tissue regeneration and immune modulation.

What does VIP spray do for CIRS?

VIP nasal spray reduces inflammation, modulates immune responses, and improves blood flow and tissue oxygenation, alleviating symptoms of CIRS. The effects of the spray are linked to the activity of the active peptide gene, a precursor molecule that plays a crucial role in regulating these processes. By targeting pathways influenced by the vasoactive intestinal peptide gene, the spray helps reduce chronic inflammation. Furthermore, research into the active peptide gene as a precursor molecule highlights its potential in managing conditions like CIRS effectively. This precursor molecule is essential in understanding how VIP can regulate inflammatory responses and improve overall health outcomes.

Does peptide nasal spray work?

Peptide nasal sprays, including VIP sprays, can be effective for conditions like CIRS, provided they are used under medical supervision and tailored to the individualā€™s needs. The VIP gene plays a crucial role in producing vasoactive intestinal peptide, which is essential for regulating immune responses and inflammation. In the context of digestion, VIP influences the intestinal lumen, supporting proper motility and fluid secretion. Understanding how the VIP gene functions can help optimize the use of VIP sprays for various health conditions, including CIRS. Moreover, research into the VIP gene continues to explore its broader therapeutic potential, including its impact on the intestinal lumen and overall gut health.

How to increase vasoactive intestinal peptide naturally?

Engage in regular exercise, maintain a healthy diet, reduce stress, and get adequate sleep to support natural VIP production, which in turn benefits the intestinal mucosa. Healthy lifestyle choices help maintain the integrity of the intestinal mucosa, supporting digestion, gut health, and cell differentiation. Additionally, proper care of the intestinal mucosa can enhance VIP function, improve nutrient absorption, and support cell differentiation in the gut lining. The action of adenylate cyclase activating polypeptide further contributes to these processes by stimulating cyclic AMP production, which supports mucosal health. This, in turn, may help promote a balanced and healthy intestinal environment, further enhancing overall gut health and cell differentiation, with adenylate cyclase activating polypeptide playing a key role in regulating these mechanisms. Adenylate cyclase activating polypeptide can thus be considered as a critical factor in maintaining optimal intestinal health and function.

What are the vasoactive intestinal peptide receptors?

The two primary VIP receptors are VPAC1 and VPAC2, which mediate its effects on smooth muscles, immune cells, mast cells, and other tissues. VIP’s interaction with mast cells plays a crucial role in regulating immune responses. Additionally, the activation of mast cells through VIP receptors can influence inflammation and tissue healing processes. VIP also plays a role in enzyme secretion, stimulating the pancreas to release digestive enzymes that aid in nutrient breakdown. This enzyme secretion is vital for proper digestion and absorption. Furthermore, the modulation of enzyme secretion through VIP interactions ensures that the digestive system operates efficiently, promoting overall gut health.

What does VIP do in the intestine?

Endogenous VIP promotes intestinal motility, stimulates water and electrolyte secretion, and regulates blood flow to support digestion and absorption. This naturally occurring peptide plays a key role in maintaining optimal gut function by enhancing the movement of food through the intestines. Additionally, VIP interacts with dendritic cells in the gut to modulate immune responses and maintain intestinal homeostasis. Endogenous VIP is crucial for maintaining hydration and electrolyte balance in the intestines, further supporting effective digestion and absorption. Through these mechanisms, including its influence on dendritic cells, endogenous VIP helps ensure proper gastrointestinal health. By interacting with dendritic cells, VIP also aids in regulating local immune responses within the gut, promoting a balanced immune system.

What does VIP peptide do?

VIP peptide acts as a signaling molecule that regulates digestion, immune responses, blood flow, and smooth muscle activity in different vascular tissues. It also interacts with nitric oxide to promote vasodilation, enhancing blood flow and nutrient delivery across different vascular tissues. Additionally, VIP works alongside nitric oxide to maintain smooth muscle function in different vascular tissues, supporting the coordinated movement of the digestive tract. Furthermore, VIP activates adenylate cyclase, an enzyme that produces cyclic AMP, playing a role in the regulation of smooth muscle relaxation and digestion. The action of adenylate cyclase activating polypeptide further amplifies the effects of VIP on vasodilation and smooth muscle function. In this way, both VIP and adenylate cyclase activating polypeptide cooperate to ensure proper digestive and vascular processes.

What are vasoactive peptides in burns?

Vasoactive peptides like VIP, substance P, and calcitonin gene-related peptide (CGRP) help regulate blood flow, inflammation, and tissue healing after burns by interacting with distinct membrane mimicking environments. These peptides influence cellular responses by binding to receptors located in distinct membrane mimicking environments, which helps modulate vascular permeability, immune cell activity, and intestinal inflammation. The ability of vasoactive peptides to function in distinct membrane mimicking environments is crucial for their role in tissue repair and regeneration following burns, as well as in managing conditions such as intestinal inflammation. Additionally, their activity in these environments supports the resolution of intestinal inflammation and promotes healing processes in damaged tissues.

What are the vasoactive substances in burns?

Substances like histamine, bradykinin, prostaglandins, and vasoactive peptides help mediate vascular permeability and inflammatory responses in the intestinal tract and other tissues during burns. These vasoactive substances play a critical role in regulating blood flow and healing within the intestinal tract, and they interact with the endocrine pancreas to support metabolic functions during stress. Their actions help maintain proper function and reduce damage to the intestinal tract as the body responds to burn injuries, while also influencing the endocrine pancreas to regulate hormone secretion. Additionally, the endocrine pancreas plays a key role in balancing glucose levels and supporting the healing process in response to the systemic stress caused by burns.

What does vasoactive peptide do?

Vasoactive peptides regulate blood flow, immune activity, and smooth muscle relaxation while modulating inflammatory responses, including their cardiovascular effects. They specifically influence smooth muscle cells in various tissues, promoting relaxation and improving circulation, which contributes to positive cardiovascular effects. VIP-containing nerves play a critical role in these processes by releasing vasoactive peptides that target smooth muscle cells. By targeting smooth muscle cells, vasoactive peptides help maintain proper blood flow and prevent excessive inflammation, with VIP-containing nerves ensuring that these functions are precisely regulated, ultimately enhancing cardiovascular effects.

What drugs are vasoactive peptides?

Drugs like somatostatin analogs, bradykinin antagonists, and synthetic VIP analogs are examples of vasoactive peptide-related therapies. Studies in VIP deficient mice have provided valuable insights into how VIP deficiency impacts gastrointestinal motility and immune function, highlighting the potential therapeutic benefits of VIP analogs. Furthermore, research involving VIP deficient mice is crucial for understanding the role of VIP in neuroprotection and inflammation, guiding the development of treatments for related disorders. The use of these therapies could offer improved outcomes for conditions like CIRS or gastrointestinal disorders observed in VIP deficient mice models.

What is the main function of VIP?

VIPā€™s primary function is to regulate smooth muscle relaxation, secretion of fluids, and immune modulation, supporting digestion, circulation, and tissue health. As a signal peptide, VIP plays a crucial role in facilitating communication between cells and tissues, particularly at nerve terminals. This signal peptide helps ensure the proper functioning of the digestive system and supports efficient nutrient absorption by regulating smooth muscle activity at the nerve terminals. Additionally, VIPā€™s action at nerve terminals plays an important role in modulating immune responses and maintaining tissue integrity.

What does vasoactive intestinal peptide do in the brain?

In the brain, vasoactive intestinal polypeptide (VIP) acts as a neurotransmitter and neuroprotective agent, supporting circadian rhythm regulation, neuronal growth, and reducing neuroinflammation by modulating pathways involving tumor necrosis factor and glucagon secretion. Vasoactive intestinal polypeptideā€™s interaction with tumor necrosis factor helps mitigate inflammation, protecting neuronal integrity. Additionally, its ability to regulate tumor necrosis factor and glucagon secretion contributes to maintaining a balanced immune response in the brain. Furthermore, vasoactive intestinal polypeptideā€™s role in glucagon secretion helps maintain metabolic balance, which indirectly supports brain function and cellular health.

What are the side effects of vasoactive intestinal peptide nasal spray?

Potential side effects include nasal irritation, headache, dizziness, or allergic reactions, though these vary depending on individual sensitivity and the mechanisms of VIP release, including pituitary adenylate cyclase activating pathways. Some individuals may experience discomfort due to altered VIP release patterns or heightened sensitivity to its effects, which can be influenced by pituitary adenylate cyclase activating activity. Proper medical supervision can help manage any adverse reactions related to VIP release and ensure safe usage, particularly in individuals with pituitary adenylate cyclase activating dysfunction.

What do vasoactive intestinal peptides do?

VIPs regulate smooth muscle tone, stimulate secretions, modulate immune responses, and promote tissue repair across various organ systems, including the genital organs. In particular, VIP plays a role in maintaining healthy blood flow to the genital organs, supporting their function and tissue health, while also influencing arterial blood pressure. Additionally, VIP’s ability to reduce inflammation and promote smooth muscle relaxation benefits the genital organs by enhancing overall vascular and immune regulation, which can help stabilize arterial blood pressure. Furthermore, VIP contributes to the regulation of arterial blood pressure through its effects on smooth muscle relaxation and vascular tone.

What does VIP do in digestion?

VIP enhances digestion by promoting intestinal motility, stimulating the secretion of digestive enzymes and bicarbonate, and maintaining gut hydration. Additionally, VIP works in conjunction with gastric inhibitory peptide, which plays a role in regulating digestive secretions and insulin release. The combined effects of VIP and gastric inhibitory peptide ensure proper nutrient absorption and digestion. By supporting motility and hydration, VIP complements the functions of gastric inhibitory peptide, further optimizing the digestive process. VIP also influences the urinary bladder, helping regulate smooth muscle tone and ensuring the proper function of the urinary system. The actions of VIP extend to the urinary bladder, where it can affect bladder contractions and maintain overall bladder health. With its wide range of effects, VIP plays a crucial role in both digestion and urinary bladder function.

How does VIP affect intestinal motility?

VIP relaxes smooth muscles in the gut, facilitating the movement of food and preventing issues like constipation or slowed digestion. Additionally, VIP contributes to maintaining normal coronary vasomotor tone, which is essential for proper cardiovascular function. It also plays a role in modulating the activity of T cells, which are key components of the immune system, ensuring a balanced immune response in the gut. By promoting smooth muscle relaxation and regulating T cells, VIP supports both digestive health and normal coronary vasomotor tone, ensuring efficient circulation and nutrient delivery. This dual role highlights VIP’s importance in regulating gut motility, influencing T cell activity, and maintaining normal coronary vasomotor tone for overall well-being.

Does VIP inhibit gastric emptying?

Yes, VIP inhibits gastric emptying by relaxing the pyloric sphincter and modulating gut motility through interactions with the VIP receptor to allow proper nutrient absorption. The VIP receptor plays a crucial role in mediating these effects, ensuring smooth muscle relaxation and optimal digestive function. Additionally, VIP helps reduce the production of proinflammatory cytokines, which can otherwise disrupt digestive processes. By targeting the VIP receptor, VIP helps regulate gastric processes, reduce proinflammatory cytokines, and support efficient nutrient assimilation, ultimately promoting a balanced digestive environment.

Reference

  1. Henning RJ, Sawmiller DR. Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res. 2001 Jan;49(1):27-37. doi: 10.1016/s0008-6363(00)00229-7. PMID: 11121793.

  2. Lucia P, Caiola S, Coppola A, Manetti LL, Maroccia E, De Martinis C, Buongiorno AM. Il peptide vasoattivointestinalenelloscompensocardiaco [Vasoactive intestinal peptide in heart failure]. Ital Heart J Suppl. 2000 May;1(5):679-85. Italian. PMID: 10834134.

  3. Unverferth DV, O’Dorisio TM, Miller MM, Uretsky BF, Magorien RD, Leier CV, Thompson ME, Hamlin RL. Human and canine ventricular vasoactive intestinal polypeptide: decrease with heart failure. J Lab Clin Med. 1986 Jul;108(1):11-6. PMID: 3711722.

  4. Benitez R, Delgado-Maroto V, Caro M, Forte-Lago I, Duran-Prado M, O’Valle F, Lichtman AH, Gonzalez-Rey E, Delgado M. Vasoactive Intestinal Peptide Ameliorates Acute Myocarditis and Atherosclerosis by Regulating Inflammatory and Autoimmune Responses. J Immunol. 2018 Jun 1;200(11):3697-3710. doi: 10.4049/jimmunol.1800122. Epub 2018 Apr 18. PMID: 29669783.

  5. DvorƔkovƔ MC. Cardioprotective role of the VIP signaling system. Drug News Perspect. 2005 Jul-Aug;18(6):387-91. doi: 10.1358/dnp.2005.18.6.927930. PMID: 16247516.

  6. Lucia P, Caiola S, Coppola A, Manetti LL, Maroccia E, Buongiorno AM, De Martinis C. Vasoactive intestinal peptide (VIP): a new neuroendocrine marker of clinical progression in chronic heart failure? ClinEndocrinol (Oxf). 2003 Dec;59(6):723-7. doi: 10.1046/j.1365-2265.2003.01913.x. PMID: 14974913.

  7. Brum JM, Bove AA, Sufan Q, Reilly W, Go VL. Action and localization of vasoactive intestinal peptide in the coronary circulation: evidence for nonadrenergic, noncholinergic coronary regulation. J Am Coll Cardiol. 1986 Feb;7(2):406-13. doi: 10.1016/s0735-1097(86)80513-7. PMID: 3944362.

  8. Kalfin R, Maulik N, Engelman RM, Cordis GA, Milenov K, Kasakov L, Das DK. Protective role of intracoronary vasoactive intestinal peptide in ischemic and reperfused myocardium. J Pharmacol Exp Ther. 1994 Feb;268(2):952-8. PMID: 8114010.

  9. Xi Y, Wu G, Ai T, Cheng N, Kalisnik JM, Sun J, Abbasi S, Yang D, Fan C, Yuan X, Wang S, Elayda M, Gregoric ID, Kantharia BK, Lin SF, Cheng J. Ionic mechanisms underlying the effects of vasoactive intestinal polypeptide on canine atrial myocardium. Circ Arrhythm Electrophysiol. 2013 Oct;6(5):976-83. doi: 10.1161/CIRCEP.113.000518. Epub 2013 Sep 17. PMID: 24046327.

  10. Smitherman TC, Popma JJ, Said SI, Krejs GJ, Dehmer GJ. Coronary hemodynamic effects of intravenous vasoactive intestinal peptide in humans. Am J Physiol. 1989 Oct;257(4 Pt 2):H1254-62. doi: 10.1152/ajpheart.1989.257.4.H1254. PMID: 2801984.

  11. Schroeder A, Loh DH, Jordan MC, Roos KP, Colwell CS. Circadian regulation of cardiovascular function: a role for vasoactive intestinal peptide. Am J Physiol Heart Circ Physiol. 2011 Jan;300(1):H241-50. doi: 10.1152/ajpheart.00190.2010. Epub 2010 Oct 15. PMID: 20952671; PMCID: PMC4116412.

  12. Duggan KA, Hodge G, Chen J, Hunter T. Vasoactive intestinal peptide infusion reverses existing myocardial fibrosis in the rat. Eur J Pharmacol. 2019 Nov 5;862:172629. doi: 10.1016/j.ejphar.2019.172629. Epub 2019 Aug 23. PMID: 31449808.

  13. Said SI. Vasoactive peptides in the lung, with special reference to vasoactive intestinal peptide. Exp Lung Res. 1982 Nov;3(3-4):343-8. doi: 10.3109/01902148209069662. PMID: 6762962.

  14. Available at https://www.atsjournals.org/doi/full/10.1164/rccm.200909-1451OC.

  15. Wu D, Lee D, Sung YK. Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review. Respir Res. 2011 Apr 11;12(1):45. doi: 10.1186/1465-9921-12-45. PMID: 21477377; PMCID: PMC3090995.

  16. Mathioudakis A, Chatzimavridou-Grigoriadou V, Evangelopoulou E, Mathioudakis G. Vasoactive intestinal Peptide inhaled agonists: potential role in respiratory therapeutics. Hippokratia. 2013;17(1):12-16.

  17. Wu D, Lee D, Sung YK. Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review. Respir Res. 2011;12(1):45. Published 2011 Apr 11. doi:10.1186/1465-9921-12-45.

  18. Ao X, Fang F, Xu F. Vasoactive intestinal peptide protects alveolar epithelial cells against hyperoxia via promoting the activation of STAT3. RegulPept. 2011 Jun 7;168(1-3):1-4. doi: 10.1016/j.regpep.2011.02.006. Epub 2011 Feb 18. PMID: 21334383.

  19. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, Funk GC, Hamilton G, Novotny C, Burian B, Block LH. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest. 2003 May;111(9):1339-46. doi: 10.1172/JCI17500. PMID: 12727925; PMCID: PMC154449.

  20. Youssef JG, Lavin P, Schoenfeld DA, Lee RA, Lenhardt R, Park DJ, Fernandez JP, Morganroth ML, Javitt JC, Jayaweera D. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial. Crit Care Med. 2022 Nov 1;50(11):1545-1554. doi: 10.1097/CCM.0000000000005660. Epub 2022 Aug 29. PMID: 36044317; PMCID: PMC9555831.

  21. Leuchte HH, Baezner C, Baumgartner RA, Bevec D, Bacher G, Neurohr C, Behr J. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J. 2008 Nov;32(5):1289-94. doi: 10.1183/09031936.00050008. PMID: 18978135.

  22. Inhalation of vasoactive intestinal peptide in pulmonary hypertension
    A single inhaled dose of aviptadil caused modest, short-lived pulmonary vasodilation, improved stroke volume, and reduced right ventricular workload in patients with chronic pulmonary hypertension without affecting systemic blood pressure. It was well tolerated, with a trend toward improved oxygenation in those with significant lung disease, warranting further study for therapeutic potential.
    You can read the abstract of the article at
    https://pubmed.ncbi.nlm.nih.gov/18978135/.Ā Ā 

  23. Zhong HL, Li PZ, Li D, Guan CX, Zhou Y. The role of vasoactive intestinal peptide in pulmonary diseases. Life Sci. 2023 Nov 1;332:122121. doi: 10.1016/j.lfs.2023.122121. Epub 2023 Sep 22. PMID: 37742737.

  24. Alessandrini F, Thakkar M, Foda HD, Said SI, Lodi R, Pakbaz H, Schraufnagel DE. Vasoactive intestinal peptide enhances lung preservation. Transplantation. 1993 Oct;56(4):964-73. doi: 10.1097/00007890-199310000-00036. PMID: 8212221.

  25. Guan CX, Zhang M, Qin XQ, Cui YR, Luo ZQ, Bai HB, Fang X. Vasoactive intestinal peptide enhances wound healing and proliferation of human bronchial epithelial cells. Peptides. 2006 Dec;27(12):3107-14. doi: 10.1016/j.peptides.2006.08.004. Epub 2006 Sep 11. PMID: 16965837.

  26. Tuncel N, Yildirim N, Gurer F, Basmak H, Uzuner K, Sahinturk V, Gursoy H. Effect of vasoactive intestinal peptide on the wound healing of alkali-burned corneas. Int J Ophthalmol. 2016 Feb 18;9(2):204-10. doi: 10.18240/ijo.2016.02.04. PMID: 26949636; PMCID: PMC4761728.

  27. Wang Y, Chen Z, Luo G, He W, Xu K, Xu R, Lei Q, Tan J, Wu J, Xing M. In-Situ-Generated Vasoactive Intestinal Peptide Loaded Microspheres in Mussel-Inspired PolycaprolactoneNanosheets Creating Spatiotemporal Releasing Microenvironment to Promote Wound Healing and Angiogenesis. ACS Appl Mater Interfaces. 2016 Mar 23;8(11):7411-21. doi: 10.1021/acsami.5b11332. Epub 2016 Mar 14. PMID: 26914154.

  28. Zhang Y, Gao N, Wu L, Lee PSY, Me R, Dai C, Xie L, Yu FX. Role of VIP and Sonic Hedgehog Signaling Pathways in Mediating Epithelial Wound Healing, Sensory Nerve Regeneration, and Their Defects in Diabetic Corneas. Diabetes. 2020 Jul;69(7):1549-1561. doi: 10.2337/db19-0870. Epub 2020 Apr 28. PMID: 32345752; PMCID: PMC7306128.

  29. Satitpitakul V, Sun Z, Suri K, Amouzegar A, Katikireddy KR, Jurkunas UV, Kheirkhah A, Dana R. Vasoactive Intestinal Peptide Promotes Corneal Allograft Survival. Am J Pathol. 2018 Sep;188(9):2016-2024. doi: 10.1016/j.ajpath.2018.05.010. Epub 2018 Aug 7. PMID: 30097165; PMCID: PMC6593256.

  30. Sun X, Huang Y, Zhang YL, Qiao D, Dai YC. Research advances of vasoactive intestinal peptide in the pathogenesis of ulcerative colitis by regulating interleukin-10 expression in regulatory B cells. World J Gastroenterol. 2020 Dec 28;26(48):7593-7602. doi: 10.3748/wjg.v26.i48.7593. PMID: 33505138; PMCID: PMC7789055.

  31. Lindblom L, Cassuto J, YregƄrd L, Tarnow P, RƤntfors J, Lƶwhagen HendƩn P. Importance of vasoactive intestinal polypeptide in the regulation of burn perfusion. Burns. 2000 Aug;26(5):435-42. doi: 10.1016/s0305-4179(99)00178-3. PMID: 10812264.

  32. Guan CX, Cui YR, Zhang M, Bai HB, Khunkhun R, Fang X. Intracellular signaling molecules involved in vasoactive intestinal peptide-mediated wound healing in human bronchial epithelial cells. Peptides. 2007 Sep;28(9):1667-73. doi: 10.1016/j.peptides.2007.07.027. Epub 2007 Aug 1. PMID: 17826179.

  33. Guan CX, Cui YR, Sun GY, Yu F, Tang CY, Li YC, Liu HJ, Fang X. Role of CREB in vasoactive intestinal peptide-mediated wound healing in human bronchial epithelial cells. Regul Pept. 2009 Feb 25;153(1-3):64-9. doi: 10.1016/j.regpep.2008.12.003. Epub 2008 Dec 24. PMID: 19136032.

  34. Shi L, Liu Y, Yang Z, Wu T, Lo HT, Xu J, Zhang J, Lin W, Zhang J, Feng L, Li G. Vasoactive Intestinal Peptide Promotes Fracture Healing in Sympathectomized Mice. Calcif Tissue Int. 2021 Jul;109(1):55-65. doi: 10.1007/s00223-021-00820-9. Epub 2021 May 17. PMID: 33999216.

  35. Gao XP, Noda Y, Rubinstein I, Paul S. Vasoactive intestinal peptide encapsulated in liposomes: effects on systemic arterial blood pressure. Life Sci. 1994;54(15):PL247-52. doi: 10.1016/0024-3205(94)00425-0. PMID: 8152324.

  36. Eriksson LS, Hagenfeldt L, Mutt V, Wahren J. Influence of vasoactive intestinal polypeptide (VIP) on splanchnic and central hemodynamics in healthy subjects. Peptides. 1989 Mar-Apr;10(2):481-4. doi: 10.1016/0196-9781(89)90062-4. PMID: 2666962.

  37. Eklund S, Jodal M, Lundgren O, Sjƶqvist A. Effects of vasoactive intestinal polypeptide on blood flow, motility and fluid transport in the gastrointestinal tract of the cat. ActaPhysiol Scand. 1979 Apr;105(4):461-8. doi: 10.1111/j.1748-1716.1979.tb00111.x. PMID: 452923.

  38. Xiao D, Kang J, Hu X. [The relationship of vasoactive intestinal peptide, other substances and the changes of nocturnal blood pressure in patients with obstructive sleep apnea syndrome]. Zhonghua Jie He He Hu Xi Za Zhi. 2000 Jun;23(6):351-4. Chinese. PMID: 11778517.

  39. Hoover DB. Effects of guinea pig vasoactive intestinal peptide on the isolated perfused guinea pig heart. Peptides. 1989 Mar-Apr;10(2):343-7. doi: 10.1016/0196-9781(89)90041-7. PMID: 2755874.

  40. Porter JP, Thrasher TN, Said SI, Ganong WF. Vasoactive intestinal peptide in the regulation of renin secretion. Am J Physiol. 1985 Jul;249(1 Pt 2):F84-9. doi: 10.1152/ajprenal.1985.249.1.F84. PMID: 3893159.

  41. Koyama S, Fujita T, Shibamoto T, Matsuda Y, Uematsu H, Jones RO. Contribution of baroreceptor reflexes to blood pressure and sympathetic responses to cholecystokinin and vasoactive intestinal peptide in anesthetized dogs. Eur J Pharmacol. 1990 Jan 17;175(3):245-51. doi: 10.1016/0014-2999(90)90561-j. PMID: 2323348.

  42. Frase LL, Gaffney FA, Lane LD, Buckey JC, Said SI, Blomqvist CG, Krejs GJ. Cardiovascular effects of vasoactive intestinal peptide in healthy subjects. Am J Cardiol. 1987 Dec 1;60(16):1356-61. doi: 10.1016/0002-9149(87)90619-9. PMID: 3687785.

  43. Henning RJ, Sawmiller DR. Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res. 2001 Jan;49(1):27-37. doi: 10.1016/s0008-6363(00)00229-7. PMID: 11121793.

  44. Bains M, Laney C, Wolfe AE, Orr M, Waschek JA, Ericsson AC, Dorsam GP. Vasoactive Intestinal Peptide Deficiency Is Associated With Altered Gut Microbiota Communities in Male and Female C57BL/6 Mice. Front Microbiol. 2019 Dec 2;10:2689. doi: 10.3389/fmicb.2019.02689. PMID: 31849864; PMCID: PMC6900961.

  45. Vu JP, Larauche M, Flores M, Luong L, Norris J, Oh S, Liang LJ, Waschek J, Pisegna JR, Germano PM. Regulation of Appetite, Body Composition, and Metabolic Hormones by Vasoactive Intestinal Polypeptide (VIP). J MolNeurosci. 2015 Jun;56(2):377-87. doi: 10.1007/s12031-015-0556-z. Epub 2015 Apr 23. PMID: 25904310; PMCID: PMC4458420.

  46. Zimmerman RP, Gates TS, Mantyh CR, Vigna SR, Welton ML, Passaro EP Jr, Mantyh PW. Vasoactive intestinal polypeptide receptor binding sites in the human gastrointestinal tract: localization by autoradiography. Neuroscience. 1989;31(3):771-83. doi: 10.1016/0306-4522(89)90440-5. PMID: 2556662.

  47. Said SI. Vasoactive intestinal peptide in the gut. Physiology and pathology. ActaGastroenterol Belg. 1982 Jul-Aug;45(7-8):310-3. PMID: 6301189.

  48. Seo S, Miyake H, Alganabi M, Janssen Lok M, O’Connell JS, Lee C, Li B, Pierro A. Vasoactive intestinal peptide decreases inflammation and tight junction disruption in experimental necrotizing enterocolitis. J Pediatr Surg. 2019 Dec;54(12):2520-2523. doi: 10.1016/j.jpedsurg.2019.08.038. Epub 2019 Aug 30. PMID: 31668399.

  49. Gonzalez-Rey E, Delgado M. Role of vasoactive intestinal peptide in inflammation and autoimmunity. Curr Opin Investig Drugs. 2005 Nov;6(11):1116-23. PMID: 16312132.

  50. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev. 2004 Jun;56(2):249-90. doi: 10.1124/pr.56.2.7. PMID: 15169929.

  51. Bednarska O, Walter SA, Casado-Bedmar M, Strƶm M, Salvo-Romero E, Vicario M, Mayer EA, Keita ƅV. Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome. Gastroenterology. 2017 Oct;153(4):948-960.e3. doi: 10.1053/j.gastro.2017.06.051. Epub 2017 Jul 13. PMID: 28711627; PMCID: PMC5623149.

  52. Yu HB, Yang H, Allaire JM, Ma C, Graef FA, Mortha A, Liang Q, Bosman ES, Reid GS, Waschek JA, Osborne LC, Sokol H, Vallance BA, Jacobson K. Vasoactive intestinal peptide promotes host defense against enteric pathogens by modulating the recruitment of group 3 innate lymphoid cells. Proc Natl Acad Sci U S A. 2021 Oct 12;118(41):e2106634118. doi: 10.1073/pnas.2106634118. PMID: 34625492; PMCID: PMC8521691.

  53. Zhongkai L, Jianxin Y, Weichang C. Vasoactive intestinal peptide promotes gut barrier function against severe acute pancreatitis. Mol Biol Rep. 2012 Apr;39(4):3557-63. doi: 10.1007/s11033-011-1129-z. Epub 2011 Jul 3. PMID: 21725849.

  54. Bai X, De Palma G, Boschetti E, Nishiharo Y, Lu J, Shimbori C, Costanzini A, Saqib Z, Kraimi N, Sidani S, Hapfelmeier S, Macpherson AJ, Verdu EF, De Giorgio R, Collins SM, Bercik P. Vasoactive Intestinal Polypeptide Plays a Key Role in the Microbial-Neuroimmune Control of Intestinal Motility. Cell Mol Gastroenterol Hepatol. 2024;17(3):383-398. doi: 10.1016/j.jcmgh.2023.11.012. Epub 2023 Dec 5. PMID: 38061549; PMCID: PMC10825443.

  55. Agibalova T, Hempel A, Maurer HC, Ragab M, Ermolova A, Wieland J, Waldherr Ɓvila de Melo C, Heindl F, Giller M, Fischer JC, Tschurtschenthaler M, Kohnke-Ertel B, Ɩllinger R, Steiger K, Demir IE, Saur D, Quante M, Schmid RM, Middelhoff M. Vasoactive intestinal peptide promotes secretory differentiation and mitigates radiation-induced intestinal injury. Stem Cell Res Ther. 2024 Oct 8;15(1):348. doi: 10.1186/s13287-024-03958-z. PMID: 39380035; PMCID: PMC11462795.

  56. Wu X, Conlin VS, Morampudi V, Ryz NR, Nasser Y, Bhinder G, Bergstrom KS, Yu HB, Waterhouse CC, Buchan AM, Popescu OE, Gibson WT, Waschek JA, Vallance BA, Jacobson K. Vasoactive intestinal polypeptide promotes intestinal barrier homeostasis and protection against colitis in mice. PLoS One. 2015 May 1;10(5):e0125225. doi: 10.1371/journal.pone.0125225. PMID: 25932952; PMCID: PMC4416880.

  57. Cochaud S, Chevrier L, Meunier AC, Brillet T, ChadƩneau C, Muller JM. The vasoactive intestinal peptide-receptor system is involved in human glioblastoma cell migration. Neuropeptides. 2010 Oct;44(5):373-83. doi: 10.1016/j.npep.2010.06.003. Epub 2010 Jul 17. PMID: 20638719.

  58. Jaggi M, Prasad S, Singh AT, Praveen R, Dutt S, Mathur A, Sharma R, Gupta N, Ahuja R, Mukherjee R, Burman AC. Anticancer activity of a peptide combination in gastrointestinal cancers targeting multiple neuropeptide receptors. Invest New Drugs. 2008 Dec;26(6):489-504. doi: 10.1007/s10637-008-9117-4. Epub 2008 Jan 24. PMID: 18217205.

  59. Said SI. Vasoactive intestinal peptide in the gut. Physiology and pathology. ActaGastroenterol Belg. 1982 Jul-Aug;45(7-8):310-3. PMID: 6301189.Moody TW, Mantey SA, Fuselier JA, Coy DH, Jensen RT. Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells. Peptides. 2007 Sep;28(9):1883-90. doi: 10.1016/j.peptides.2007.04.017. Epub 2007 May 6. PMID: 17580098; PMCID: PMC2742204.

  60. Iwasaki M, Akiba Y, Kaunitz JD. Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system. F1000Res. 2019 Sep 12;8:F1000 Faculty Rev-1629. doi: 10.12688/f1000research.18039.1. PMID: 31559013; PMCID: PMC6743256.

  61. Xu CL, Guo Y, Qiao L, Ma L, Cheng YY. Recombinant expressed vasoactive intestinal peptide analogue ameliorates TNBS-induced colitis in rats. World J Gastroenterol. 2018 Feb 14;24(6):706-715. doi: 10.3748/wjg.v24.i6.706. PMID: 29456409; PMCID: PMC5807673.

  62. Li GH, Qian W, Song GQ, Hou XH. Effect of vasoactive intestinal peptide on gastric adenocarcinoma. J Gastroenterol Hepatol. 2007 Aug;22(8):1328-35. doi: 10.1111/j.1440-1746.2007.04947.x. Epub 2007 Jun 7. PMID: 17559364.

  63. Gelber E, Granoth R, Fridkin M, Dreznik Z, Brenneman DE, Moody TW, Gozes I. A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines. Cancer. 2001 Oct 15;92(8):2172-80. doi: 10.1002/1097-0142(20011015)92:8<2172::aid-cncr1560>3.0.co;2-4. PMID: 11596035.

  64. Hara M, Takeba Y, Iiri T, Ohta Y, Ootaki M, Watanabe M, Watanabe D, Koizumi S, Otsubo T, Matsumoto N. Vasoactive intestinal peptide increases apoptosis of hepatocellular carcinoma by inhibiting the cAMP/Bcl-xL pathway. Cancer Sci. 2019 Jan;110(1):235-244. doi: 10.1111/cas.13861. Epub 2018 Dec 4. PMID: 30390393; PMCID: PMC6317926.

  65. Smalley SG, Barrow PA, Foster N. Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease. ClinExpImmunol. 2009;157(2):225-234. doi:10.1111/j.1365-2249.2009.03956.x.

  66. Gonzalez-Rey E, Anderson P, Delgado M. Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy. Ann Rheum Dis. 2007;66Suppl 3(Suppl 3):iii70-iii76. doi:10.1136/ard.2007.078519.

  67. Li JM, Darlak KA, Southerland L, Hossain MS, Jaye DL, Josephson CD, Rosenthal H, Waller EK. VIPhyb, an antagonist of vasoactive intestinal peptide receptor, enhances cellular antiviral immunity in murine cytomegalovirus infected mice. PLoS One. 2013 May 27;8(5):e63381. doi: 10.1371/journal.pone.0063381. PMID: 23723978; PMCID: PMC3664580.

  68. Song X, Pi S, Gao Y, Zhou F, Yan S, Chen Y, Qiao L, Dou X, Shao D, Xu C. The Role of Vasoactive Intestinal Peptide and Mast Cells in the Regulatory Effect of Lactobacillus casei ATCC 393 on Intestinal Mucosal Immune Barrier. Front Immunol. 2021 Nov 25;12:723173. doi: 10.3389/fimmu.2021.723173. PMID: 34899686; PMCID: PMC8657605.

  69. Wang Y, Mei Y, Bao S, Xu L. Vasoactive intestinal polypeptide enhances oral tolerance by regulating both cellular and humoral immune responses. Clin Exp Immunol. 2007 Apr;148(1):178-87. doi: 10.1111/j.1365-2249.2007.03322.x. PMID: 17349016; PMCID: PMC1868860.

  70. Pascal M, Kazakov A, Chevalier G, Dubrule L, Deyrat J, Dupin A, Saha S, Jagot F, Sailor K, Dulauroy S, Moigneu C, Belkaid Y, Lepousez G, Lledo PM, Wilhelm C, Eberl G. The neuropeptide VIP potentiates intestinal innate type 2 and type 3 immunity in response to feeding. Mucosal Immunol. 2022 Apr;15(4):629-641. doi: 10.1038/s41385-022-00516-9. Epub 2022 May 2. PMID: 35501356.

  71. Guan L, Yu D, Wu GH, Ning HJ, He SD, Li SS, Hu TY, Yang G, Liu ZQ, Yu HQ, Sun XZ, Liu ZG, Yang PC. Vasoactive intestinal peptide is required in the maintenance of immune regulatory competency of immune regulatory monocytes. Clin Exp Immunol. 2019 May;196(2):276-286. doi: 10.1111/cei.13259. Epub 2019 Jan 30. PMID: 30636174; PMCID: PMC6468183.

  72. Sun X, Huang Y, Zhang YL, Qiao D, Dai YC. Research advances of vasoactive intestinal peptide in the pathogenesis of ulcerative colitis by regulating interleukin-10 expression in regulatory B cells. World J Gastroenterol. 2020 Dec 28;26(48):7593-7602. doi: 10.3748/wjg.v26.i48.7593. PMID: 33505138; PMCID: PMC7789055.

  73. Yadav M, Goetzl EJ. Vasoactive intestinal peptide-mediated Th17 differentiation: an expanding spectrum of vasoactive intestinal peptide effects in immunity and autoimmunity. Ann N Y Acad Sci. 2008 Nov;1144:83-9. doi: 10.1196/annals.1418.020. PMID: 19076367.

  74. intestinal peptide (VIP): its therapeutic potential in inflammatory disease. Clin Exp Immunol. 2009 Aug;157(2):225-34. doi: 10.1111/j.1365-2249.2009.03956.x. PMID: 19604262; PMCID: PMC2730848.

  75. Voice JK, Grinninger C, Kong Y, Bangale Y, Paul S, Goetzl EJ. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J Immunol. 2003 Jan 1;170(1):308-14. doi: 10.4049/jimmunol.170.1.308. PMID: 12496414.

  76. Sun X, Guo C, Zhao F, Zhu J, Xu Y, Liu ZQ, Yang G, Zhang YY, Gu X, Xiao L, Liu Z, Yang PC. Vasoactive intestinal peptide stabilizes intestinal immune homeostasis through maintaining interleukin-10 expression in regulatory B cells. Theranostics. 2019 Apr 13;9(10):2800-2811. doi: 10.7150/thno.34414. PMID: 31244924; PMCID: PMC6568172.

  77. Delgado M, Abad C, Martinez C, Juarranz MG, Arranz A, Gomariz RP, Leceta J. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J Mol Med (Berl). 2002 Jan;80(1):16-24. doi: 10.1007/s00109-001-0291-5. Epub 2001 Oct 17. PMID: 11862320.

  78. White CM, Ji S, Cai H, Maudsley S, Martin B. Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders. CNS NeurolDisord Drug Targets. 2010;9(5):661-666. doi:10.2174/187152710793361595.

  79. Deng G, Jin L. The effects of vasoactive intestinal peptide in neurodegenerative disorders. Neurol Res. 2017 Jan;39(1):65-72. doi: 10.1080/01616412.2016.1250458. Epub 2016 Oct 27. PMID: 27786097.

  80. Korkmaz OT, Ay H, Aytan N, Carreras I, Kowall NW, Dedeoglu A, Tuncel N. Vasoactive Intestinal Peptide Decreases Ī²-Amyloid Accumulation and Prevents Brain Atrophy in the 5xFAD Mouse Model of Alzheimer’s Disease. J Mol Neurosci. 2019 Jul;68(3):389-396. doi: 10.1007/s12031-018-1226-8. Epub 2018 Nov 29. PMID: 30498985.

  81. Delgado M, Ganea D. Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J. 2003 Oct;17(13):1922-4. doi: 10.1096/fj.02-1029fje. Epub 2003 Aug 15. PMID: 12923064.

  82. Korkmaz OT, TunƧel N. Advantages of Vasoactive Intestinal Peptide for the Future Treatment of Parkinson’s Disease. Curr Pharm Des. 2018;24(39):4693-4701. doi: 10.2174/1381612825666190111150953. PMID: 30636594.

  83. Hill JM. Vasoactive intestinal peptide in neurodevelopmental disorders: therapeutic potential. Curr Pharm Des. 2007;13(11):1079-89. doi: 10.2174/138161207780618975. PMID: 17430171.

  84. simon RA, Barazanji N, Jones MP, Bednarska O, Icenhour A, Engstrƶm M, Hamilton JP, Keita ƅV, Walter S. Vasoactive intestinal polypeptide plasma levels associated with affective symptoms and brain structure and function in healthy females. Sci Rep. 2021 Jan 14;11(1):1406. doi: 10.1038/s41598-020-80873-2. PMID: 33446759; PMCID: PMC7809454.

Other Peptides

Selank

Tranexamic

Ginsenoside Rg3

GLP-1

Kisspeptin

Success Stories

men testimonial before after

At the age of 60, I look and feel better than I ever have in my entire life! Switching my health program and hormone replacement therapy regimen over to Genemedics was one of the best decisions Iā€™ve ever made in my life! Genemedics and Dr George have significantly improved my quality of life and also dramatically improved my overall health. I hav...
Nick Cassavetes ,60 yrs old Movie Director (ā€œThe Notebookā€, ā€œJohn Qā€, ā€œAlpha Dogā€), Actor and Writer

See All Menā€™s Testimonials

Call 800-277-4041 for a Free Consultation

What to expect during your consultation:
  • Usually takes 15-30 minutes
  • Completely confidential
  • No obligation to purchase anything
  • We will discuss your symptoms along with your health and fitness goals
  • Free post-consult access for any additional questions you may have

About

GenemedicsĀ® Health Institute is a global premier institute dedicated to revolutionizing health and medicine through healthy lifestyle education, guidance and accountability in harmony with functional medicine. Our physician-supervised health programs are personally customized to help you reach your health and fitness goals while looking and feeling better than ever.

Quick Links

Our Services

Ā Our Locations

genemedics logo

280 North Old Woodward Ave. Suite 210 Birmingham MI 48009,USA

800-277-4041

info@genemedics.com

© Copyright Genemedics Health Institute. All Rights Reserved. Privacy Policy.

Back to Top
-

Free Consultation

STEPS AWAY FROM A YOUNGER. HEALTHIER YOU!

Call 800-277-4041 for a Free Consultation

What to expect during your consultation:

  • Usually takes 15-30 minutes
  • Completely confidential
  • No obligation to purchase anything
  • We will discuss your symptoms along with your health and fitness goals
  • Free post-consult access for any additional questions you may have
Captch Background